---
document_datetime: 2025-12-21 12:24:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fetcroja.html
document_name: fetcroja.html
version: success
processing_time: 0.1113298
conversion_datetime: 2025-12-24 14:32:08.500704
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fetcroja

[RSS](/en/individual-human-medicine.xml/67298)

##### Authorised

This medicine is authorised for use in the European Union

cefiderocol Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fetcroja](#news-on)
- [More information on Fetcroja](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Fetcroja is an antibiotic used in adults to treat infections caused by bacteria classed as aerobic Gram-negative bacteria. It is for use when other treatments might not work.

Fetcroja contains the active substance cefiderocol.

Expand section

Collapse section

## How is Fetcroja used?

Fetcroja can only be obtained with a prescription. It should only be used after taking advice from a doctor with appropriate experience of managing patients with infectious diseases.

Fetcroja is given by infusion (drip) into a vein over 3 hours. The usual dose is 2 g given every 8 hours and the duration of treatment depends on the nature of the infection.

For more information about using Fetcroja, see the package leaflet or contact your doctor or pharmacist.

## How does Fetcroja work?

The active substance in Fetcroja, cefiderocol, belongs to the cephalosporin class of antibiotics. It uses the bacteria's own system for importing iron to enter the bacterial cell, where it blocks the formation of the bacterial cell wall, killing the bacteria.

## What benefits of Fetcroja have been shown in studies?

Fetcroja was tested in 2 main studies involving patients with various infections caused by Gram-negative bacteria.

In the first study, involving 452 adults with complicated urinary tract infection, 73% of patients treated with Fetcroja were cured (based on lack of symptoms and tests for bacteria in the urine) compared with 55% of patients treated with imipenem and cilastatin given together.

The second study involved 152 adults with various serious infections caused by bacteria that were resistant to carbapenems (could not be killed by antibiotics called carbapenems). For lung infections, 50% of patients treated with Fetcroja were cured based on a lack of symptoms, compared with 53% of those treated with the best alternative treatment. For bloodstream infections, these figures were 44% and 43%, respectively. For complicated urinary tract infections, 53% of patients treated with Fetcroja were cleared of disease-causing bacteria in the urine compared with 20% of patients receiving the best alternative treatment.

## What are the risks associated with Fetcroja?

The most common side effects (which may affect up to 1 in 10 people) were diarrhoea, vomiting, nausea (feeling sick) and cough. For the full list of side effects with Fetcroja, see the package leaflet.

Fetcroja must not be used in patients who are hypersensitive (allergic) to any cephalosporin antibiotic or who have had a severe reaction to the broader class of beta-lactam antibiotics (such as penicillins or carbapenems). For the full list of restrictions, see the package leaflet.

## Why is Fetcroja authorised in the EU?

The European Medicines Agency noted that the number of patients in the main studies was small. However, taken together with laboratory studies and studies on how the medicine works in the body, there was sufficient evidence that Fetcroja is effective against infections caused by aerobic Gram- negative bacteria. The Agency therefore decided that Fetcroja's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fetcroja?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fetcroja have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fetcroja are continuously monitored. Side effects reported with Fetcroja are carefully evaluated and any necessary action taken to protect patients.

## Other information about Fetcroja

Fetcroja received a marketing authorisation valid throughout the EU on 23 April 2020.

Fetcroja : EPAR - Medicine overview

Reference Number: EMA/115665/2020

English (EN) (106.82 KB - PDF)

**First published:** 29/04/2020

**Last updated:** 04/05/2020

[View](/en/documents/overview/fetcroja-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-254)

български (BG) (130.68 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/bg/documents/overview/fetcroja-epar-medicine-overview_bg.pdf)

español (ES) (107.2 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/es/documents/overview/fetcroja-epar-medicine-overview_es.pdf)

čeština (CS) (128.98 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/cs/documents/overview/fetcroja-epar-medicine-overview_cs.pdf)

dansk (DA) (107.21 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/da/documents/overview/fetcroja-epar-medicine-overview_da.pdf)

Deutsch (DE) (110.4 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/de/documents/overview/fetcroja-epar-medicine-overview_de.pdf)

eesti keel (ET) (96.37 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/et/documents/overview/fetcroja-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.96 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/el/documents/overview/fetcroja-epar-medicine-overview_el.pdf)

français (FR) (108.32 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/fr/documents/overview/fetcroja-epar-medicine-overview_fr.pdf)

hrvatski (HR) (127.71 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/hr/documents/overview/fetcroja-epar-medicine-overview_hr.pdf)

italiano (IT) (106.42 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/it/documents/overview/fetcroja-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (136.9 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/lv/documents/overview/fetcroja-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (128.54 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/lt/documents/overview/fetcroja-epar-medicine-overview_lt.pdf)

magyar (HU) (127.53 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/hu/documents/overview/fetcroja-epar-medicine-overview_hu.pdf)

Malti (MT) (129.04 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/mt/documents/overview/fetcroja-epar-medicine-overview_mt.pdf)

Nederlands (NL) (127.54 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/nl/documents/overview/fetcroja-epar-medicine-overview_nl.pdf)

polski (PL) (131.49 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/pl/documents/overview/fetcroja-epar-medicine-overview_pl.pdf)

português (PT) (107.91 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/pt/documents/overview/fetcroja-epar-medicine-overview_pt.pdf)

română (RO) (126.38 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/ro/documents/overview/fetcroja-epar-medicine-overview_ro.pdf)

slovenčina (SK) (128.32 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/sk/documents/overview/fetcroja-epar-medicine-overview_sk.pdf)

slovenščina (SL) (127 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/sl/documents/overview/fetcroja-epar-medicine-overview_sl.pdf)

Suomi (FI) (104.82 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/fi/documents/overview/fetcroja-epar-medicine-overview_fi.pdf)

svenska (SV) (106.05 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

04/05/2020

[View](/sv/documents/overview/fetcroja-epar-medicine-overview_sv.pdf)

Fetcroja : EPAR - Risk-management-plan summary

English (EN) (336.06 KB - PDF)

**First published:** 29/04/2020

[View](/en/documents/rmp-summary/fetcroja-epar-risk-management-plan-summary_en.pdf)

## Product information

Fetcroja : EPAR - Product information

English (EN) (591.05 KB - PDF)

**First published:** 29/04/2020

**Last updated:** 22/01/2025

[View](/en/documents/product-information/fetcroja-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-683)

български (BG) (672.32 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/bg/documents/product-information/fetcroja-epar-product-information_bg.pdf)

español (ES) (590.23 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/es/documents/product-information/fetcroja-epar-product-information_es.pdf)

čeština (CS) (665.97 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/cs/documents/product-information/fetcroja-epar-product-information_cs.pdf)

dansk (DA) (543.22 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/da/documents/product-information/fetcroja-epar-product-information_da.pdf)

Deutsch (DE) (625.94 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/de/documents/product-information/fetcroja-epar-product-information_de.pdf)

eesti keel (ET) (624.21 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/et/documents/product-information/fetcroja-epar-product-information_et.pdf)

ελληνικά (EL) (682.36 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/el/documents/product-information/fetcroja-epar-product-information_el.pdf)

français (FR) (653.96 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/fr/documents/product-information/fetcroja-epar-product-information_fr.pdf)

hrvatski (HR) (640.5 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/hr/documents/product-information/fetcroja-epar-product-information_hr.pdf)

íslenska (IS) (496.53 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/is/documents/product-information/fetcroja-epar-product-information_is.pdf)

italiano (IT) (558.28 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/it/documents/product-information/fetcroja-epar-product-information_it.pdf)

latviešu valoda (LV) (587.55 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/lv/documents/product-information/fetcroja-epar-product-information_lv.pdf)

lietuvių kalba (LT) (647.7 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/lt/documents/product-information/fetcroja-epar-product-information_lt.pdf)

magyar (HU) (616.07 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/hu/documents/product-information/fetcroja-epar-product-information_hu.pdf)

Malti (MT) (755.21 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/mt/documents/product-information/fetcroja-epar-product-information_mt.pdf)

Nederlands (NL) (544.81 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/nl/documents/product-information/fetcroja-epar-product-information_nl.pdf)

norsk (NO) (533.08 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/no/documents/product-information/fetcroja-epar-product-information_no.pdf)

polski (PL) (685.72 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/pl/documents/product-information/fetcroja-epar-product-information_pl.pdf)

português (PT) (581.99 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/pt/documents/product-information/fetcroja-epar-product-information_pt.pdf)

română (RO) (654.93 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/ro/documents/product-information/fetcroja-epar-product-information_ro.pdf)

slovenčina (SK) (660.54 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/sk/documents/product-information/fetcroja-epar-product-information_sk.pdf)

slovenščina (SL) (582.66 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/sl/documents/product-information/fetcroja-epar-product-information_sl.pdf)

Suomi (FI) (519.86 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/fi/documents/product-information/fetcroja-epar-product-information_fi.pdf)

svenska (SV) (574.82 KB - PDF)

**First published:**

29/04/2020

**Last updated:**

22/01/2025

[View](/sv/documents/product-information/fetcroja-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0022 13/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fetcroja : EPAR - All available presentations

English (EN) (39.88 KB - PDF)

**First published:** 29/04/2020

[View](/en/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-342)

български (BG) (49.11 KB - PDF)

**First published:**

29/04/2020

[View](/bg/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_bg.pdf)

español (ES) (40.16 KB - PDF)

**First published:**

29/04/2020

[View](/es/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_es.pdf)

čeština (CS) (49.54 KB - PDF)

**First published:**

29/04/2020

[View](/cs/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_cs.pdf)

dansk (DA) (42.33 KB - PDF)

**First published:**

29/04/2020

[View](/da/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_da.pdf)

Deutsch (DE) (42.55 KB - PDF)

**First published:**

29/04/2020

[View](/de/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_de.pdf)

eesti keel (ET) (40.46 KB - PDF)

**First published:**

29/04/2020

[View](/et/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_et.pdf)

ελληνικά (EL) (48.57 KB - PDF)

**First published:**

29/04/2020

[View](/el/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_el.pdf)

français (FR) (40.17 KB - PDF)

**First published:**

29/04/2020

[View](/fr/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_fr.pdf)

hrvatski (HR) (57.83 KB - PDF)

**First published:**

29/04/2020

[View](/hr/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_hr.pdf)

íslenska (IS) (42.36 KB - PDF)

**First published:**

29/04/2020

[View](/is/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_is.pdf)

italiano (IT) (39.93 KB - PDF)

**First published:**

29/04/2020

[View](/it/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_it.pdf)

latviešu valoda (LV) (59.22 KB - PDF)

**First published:**

29/04/2020

[View](/lv/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_lv.pdf)

lietuvių kalba (LT) (57.33 KB - PDF)

**First published:**

29/04/2020

[View](/lt/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_lt.pdf)

magyar (HU) (49.82 KB - PDF)

**First published:**

29/04/2020

[View](/hu/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_hu.pdf)

Malti (MT) (58.82 KB - PDF)

**First published:**

29/04/2020

[View](/mt/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_mt.pdf)

Nederlands (NL) (40.2 KB - PDF)

**First published:**

29/04/2020

[View](/nl/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_nl.pdf)

norsk (NO) (41.75 KB - PDF)

**First published:**

29/04/2020

[View](/no/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_no.pdf)

polski (PL) (60.65 KB - PDF)

**First published:**

29/04/2020

[View](/pl/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_pl.pdf)

português (PT) (41.02 KB - PDF)

**First published:**

29/04/2020

[View](/pt/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_pt.pdf)

română (RO) (57.31 KB - PDF)

**First published:**

29/04/2020

[View](/ro/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_ro.pdf)

slovenčina (SK) (58.31 KB - PDF)

**First published:**

29/04/2020

[View](/sk/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_sk.pdf)

slovenščina (SL) (48.88 KB - PDF)

**First published:**

29/04/2020

[View](/sl/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_sl.pdf)

Suomi (FI) (40.26 KB - PDF)

**First published:**

29/04/2020

[View](/fi/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_fi.pdf)

svenska (SV) (40.18 KB - PDF)

**First published:**

29/04/2020

[View](/sv/documents/all-authorised-presentations/fetcroja-epar-all-available-presentations_sv.pdf)

## Product details

Name of medicine Fetcroja Active substance cefiderocol sulfate tosilate International non-proprietary name (INN) or common name cefiderocol Therapeutic area (MeSH) Gram-Negative Bacterial Infections Anatomical therapeutic chemical (ATC) code J01D

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Fetcroja is indicated for the treatment of infections   due to aerobic Gram-negative organisms in adults with limited treatment options (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/004829 Marketing authorisation holder

Shionogi B.V.

Herengracht 464

Marketing authorisation issued 23/04/2020 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fetcroja : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (201.85 KB - PDF)

**First published:** 28/07/2020

**Last updated:** 22/01/2025

[View](/en/documents/procedural-steps-after/fetcroja-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Fetcroja-PAM-0000303390 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2517542

English (EN) (2.78 MB - PDF)

**First published:** 18/12/2025

[View](/en/documents/variation-report/fetcroja-pam-0000303390-epar-assessment-report_en.pdf)

Fetcroja-PAM-0000268740 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2101476

English (EN) (1.76 MB - PDF)

**First published:** 06/08/2025

[View](/en/documents/variation-report/fetcroja-pam-0000268740-epar-assessment-report_en.pdf)

Fetcroja-H-C-004829-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/513625/2023

English (EN) (1.41 MB - PDF)

**First published:** 21/11/2023

[View](/en/documents/variation-report/fetcroja-h-c-004829-p46-005-epar-assessment-report_en.pdf)

Fetcroja-H-C-PSUSA-00010849-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/711450/2022

English (EN) (102.55 KB - PDF)

**First published:** 06/09/2022

[View](/en/documents/scientific-conclusion/fetcroja-h-c-psusa-00010849-202111-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Fetcroja : EPAR - Public assessment report

Adopted

Reference Number: EMA/136096/2020

English (EN) (5.72 MB - PDF)

**First published:** 29/04/2020

[View](/en/documents/assessment-report/fetcroja-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Fetcroja

Adopted

Reference Number: EMA/CHMP/73102/2020

English (EN) (150.23 KB - PDF)

**First published:** 28/02/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-fetcroja_en.pdf)

#### News on Fetcroja

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2020) 28/02/2020

#### More information on Fetcroja

- [EMEA-002133-PIP01-17-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002133-pip01-17-m04)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2025

## Share this page

[Back to top](#main-content)